FDA approves first-ever Ebola prevention vaccine
The Food and Drug Administration (FDA) announced Thursday that it has approved a vaccine that would prevent the Ebola virus.
The vaccine, called Ervebo, prevents Ebola virus disease, caused by Zaire ebolavirus in people 18 and older, according to an FDA statement.
Anna Abram, FDA deputy commissioner for policy, legislation and international affairs, said in the statement that while the risk of getting Ebola is low in the U.S., the government is “deeply committed” to combating outbreaks in Africa.
She said that the FDA’s efforts reflect its “unwavering dedication to leveraging our expertise to facilitate the development and availability of safe and effective medical products to address urgent public health needs.”
Congo is currently experiencing an Ebola outbreak that has killed more than 2,000 people.
A previous outbreak in West Africa that lasted from 2014 to 2016 killed more than 11,000 people.
The Ervebo vaccine, manufactured by Merck, was approved in Europe last month.
The Hill has removed its comment section, as there are many other forums for readers to participate in the conversation. We invite you to join the discussion on Facebook and Twitter.